Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

Excipient producers and industry observers share their perspectives on innovation for excipients.

Tracking the Potential of Excipients

What makes a drug ripe for respiratory delivery?

Journey to the Center of the Lung

Stefan Schneid works in the Department of Pharmaceutics at the University of Erlangen in Erlangen, Germany.

Henning Gieseler, PhD, works in the Department of Pharmaceutics at the University of Erlangen, Erlangen, Germany 91058. tel. +49 9131 85 29545, gieseler@freeze-drying.eu.

Mannitol is the most commonly used bulking agent in freeze-drying formulation design. The benefit of using mannitol is that it crystallizes during freezing and permits drying processes at higher product temperatures, and thus with higher sublimation rates relative to purely amorphous systems (1). Mannitol, however, is known to form different crystalline modifications which compromises reproducibility of product characteristics and storage stability due to phase transformations (2, 3).

Peer-Reviewed Technical Note: Influence of Common Excipients on the Crystalline Modification of Freeze-Dried Mannitol

The European Union's REACH initiative has the potential to affect the flow of chemicals into the pharmaceutical suppy chain.

A Changing Path in Global Sourcing

Scientists at The Wistar Institute are taking further steps into understanding a gene regulator that can lead them closer to developing new cancer therapies.

Gene Regulator Key to New Cancer Therapies

Contract manufacturers expand capabilities in aseptic processing, clinical-trial materials supply, and cytotoxic manufacturing.

Charting Dosage-Form Manufacturing

An updated book summarizes recent research for formulators and drug-delivery specialists.

Designing and Delivering Therapeutic Proteins

Researchers and process chemists share approaches in synthesis of active ingredients and pharmaceutical intermediates.

Custom Synthesis of APIs

Pharmaceutical manufacturers often avoid putting new excipients in their formulations for fear of more regulatory oversight. IPEC has a solution.

Inside IPEC: New Excipient Evaluation Procedure

A surge in capacity in contract microbial and mammalian cell-culture is underway to meet rising production needs for biopharmaceuticals.

APIs and Excipients